What’s the current market cap for Doximity stock?

Doximity (DOCS) has a market cap of $3.5B as of May 23, 2026.

What is the P/E ratio for Doximity stock?

The price to earnings (P/E) ratio for Doximity (DOCS) stock is 19.79 as of May 23, 2026.

Does Doximity stock pay dividends?

No, Doximity (DOCS) stock does not pay dividends to its shareholders as of May 23, 2026.

When is the next Doximity dividend payment date?

Doximity (DOCS) stock does not pay dividends to its shareholders.

What is the beta indicator for Doximity?

Doximity (DOCS) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Doximity stock | $DOCS Share Price

13:30

15:10

16:45

18:25

20:00

About Doximity

Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.

Ticker

$DOCS

Sector

Health

Primary listing

NYSE

Employees

880

Headquarters

San Francisco, United States

Website

www.doximity.com

Doximity Metrics

BasicAdvanced

$3.5bn

19.79

$0.98

1.35

What the Analysts think about Doximity

Analyst ratings (Buy, Hold, Sell) for Doximity stock.

Bulls say / Bears say

Doximity's revenue in Q2 fiscal 2026 increased 23% year-over-year to $168.53 million, beating the $157.61 million consensus estimate and showing strong platform demand (Reuters).

Doximity's AI suite usage in Q1 fiscal 2026 grew fivefold year-over-year, highlighting a rapid increase in adoption of its AI-driven clinical tools (Reuters).

A record 650,000 prescribers used Doximity's workflow tools in Q2 fiscal 2026, demonstrating high member engagement and platform retention (Reuters).

Revenue growth decelerated in Q3 fiscal 2026 to 10% year-over-year with $185.1 million in revenue, down from 23% growth in Q2, signalling a slowdown in momentum (Reuters).

Net income in Q3 fiscal 2026 declined 18% year-over-year to $61.6 million despite revenue gains, indicating profit pressures from increased investments (Reuters).

Full-year fiscal 2026 revenue guidance was narrowed to $642.5–643.5 million, suggesting limited upside for investors and heightening concerns over growth ceilings (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 26 Apr 2026.

Doximity Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Doximity Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DOCS

Capital at risk

Market closed

Upcoming events

No upcoming events